Clinical Medicine Equipment With Vaccine For COVID-19 Applications
-
Manufactured by Novavaxbased in USA
In March 2020, we announced positive top-line results from our Phase 3 clinical trial of our nanoparticle seasonal quadrivalent influenza vaccine candidate, including our proprietary Matrix-M™ adjuvant (NanoFlu™). The trial was a randomized, observer-blinded, active-controlled trial in approximately 2,652 healthy older adults (aged 65 years and older) across 19 clinical sites in the ...
-
Manufactured by Novavaxbased in USA
Older adults (aged 60 years and older) are at increased risk for RSV disease due in part to immunosenescence, the age-related decline in the human immune system. RSV infection can also lead to exacerbation of underlying comorbidities such as chronic obstructive pulmonary disease, asthma, and congestive heart failure. In the United States alone, a reported RSV incidence rate of 5.5% in older ...
-
Manufactured by Novavaxbased in USA
With the ongoing development of our NanoFlu™ and RSV F vaccines, a strong rationale exists for developing a combination respiratory vaccine that is designed to protect susceptible populations against both diseases. Although testing is at an early stage, we believe that a combination vaccine against both seasonal influenza and RSV may be ...
-
Manufactured by Novavaxbased in USA
ResVax is our aluminum-adjuvanted RSV F vaccine for infants via maternal immunization. RSV is the most common cause of lower respiratory tract infections (LRTI) and the leading viral cause of severe lower respiratory tract disease in infants and young children worldwide. In the United States, RSV is the leading cause of hospitalization of infants and, globally, is second only to malaria as a ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you